Dr. Daniels Discusses Treatment Options in Thyroid Cancer

Gregory A. Daniels, MD, PhD
Published Online: Friday, Oct 27, 2017



Gregory A. Daniels, MD, PhD, medical oncologist, associate professor of medicine, UC San Diego Health, discusses treatment options for patients with thyroid cancer.

The 2 FDA-approved agents for the treatment of patients with thyroid cancer are sorafenib (Nexavar) and lenvatinib (Lenvima). These are tyrosine kinase inhibitors that target VEGF1, VEGF2, and VEGF3, but these are not necessarily the driver mutations, says Daniels.

The hype of personalized medicine now is making its way into thyroid cancer, says Daniels, and a genetic-based approach to treatment may be in the future for this disease.
 


Gregory A. Daniels, MD, PhD, medical oncologist, associate professor of medicine, UC San Diego Health, discusses treatment options for patients with thyroid cancer.

The 2 FDA-approved agents for the treatment of patients with thyroid cancer are sorafenib (Nexavar) and lenvatinib (Lenvima). These are tyrosine kinase inhibitors that target VEGF1, VEGF2, and VEGF3, but these are not necessarily the driver mutations, says Daniels.

The hype of personalized medicine now is making its way into thyroid cancer, says Daniels, and a genetic-based approach to treatment may be in the future for this disease.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x